Kiniksa Pharmaceuticals International, plc (KNSA) Earnings History
Profitable10 years of earnings data (2016–2025) · Positive TTM net income
Loading earnings history...
Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Overview
As of October 3, 2026, Kiniksa Pharmaceuticals International, plc (KNSA) reported trailing twelve-month net income of $81M, reflecting +225.0% year-over-year growth. The company earned $0.97 per diluted share over the past four quarters, with a net profit margin of 8.7%.
Looking at the long-term picture, KNSA's historical earnings data spans multiple years. The company achieved its highest annual net income of $183M in fiscal 2022.
Kiniksa Pharmaceuticals International, plc maintains positive profitability with a gross margin of 54.6%, operating margin of 11.4%, and net margin of 8.7%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including ARDX (-$56M net income, -15.1% margin), PRAX (-$339M net income), RCUS (-$452M net income, -142.9% margin), KNSA has outperformed on profitability metrics. Compare KNSA vs ARDX →
KNSA Earnings vs Peers
Earnings metrics vs comparable public companies
KNSA Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $59M | +236.6% | $77M | $0.75 | 8.7% | 11.4% |
| 2024 | -$43M | -406.7% | -$46M | $-0.60 | -10.2% | -10.8% |
| 2023 | $14M | -92.3% | -$25M | $0.20 | 5.2% | -9.3% |
| 2022 | $183M | +216.1% | $10M | $2.60 | 83.3% | 4.4% |
| 2021 | -$158M | +2.1% | -$157M | $-2.30 | -409.7% | -406.4% |
| 2020 | -$161M | +0.3% | -$157M | $-2.61 | - | - |
| 2019 | -$162M | -56.8% | -$170M | $-2.99 | - | - |
| 2018 | -$103M | -59.1% | -$108M | $-3.49 | - | - |
| 2017 | -$65M | -170.6% | -$65M | $-2.00 | - | - |
| 2016 | -$24M | - | -$24M | $-0.74 | - | - |
Download Data
Export KNSA earnings history in CSV or JSON format
Free sign-in required to download data
KNSA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KNSA — Frequently Asked Questions
Quick answers to the most common questions about buying KNSA stock.
What is KNSA earnings per share (EPS)?
KNSA trailing twelve-month (TTM) diluted EPS is $0.97, reflecting +225.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Kiniksa Pharmaceuticals International, plc's net income?
Kiniksa Pharmaceuticals International, plc (KNSA) trailing twelve-month net income is $81M as of 2025. Earnings grew +225.0% year-over-year.
Is KNSA profitable?
Yes, KNSA is profitable with a TTM net income of $81M and a net profit margin of +8.7%.
What is KNSA's earnings growth rate?
KNSA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: -33.9%, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are KNSA's profit margins?
Kiniksa Pharmaceuticals International, plc net profit margin is +8.7%, operating margin is +11.4%, and gross margin is +54.6%. Margins are within a typical range for the sector. Return on Equity is +11.7%.
Is KNSA growing earnings?
Yes, KNSA earnings are accelerating — EPS growth of +225.0% exceeds the 5-year CAGR of N/A. TTM net income reached $81M. Earnings momentum is strengthening.
What was KNSA's best earnings year?
Kiniksa Pharmaceuticals International, plc's highest annual net income on record is $183M, achieved in fiscal year 2022. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were KNSA's earnings last quarter?
KNSA's most recent reported quarter was Q2 2026. Net income was $25M with diluted EPS of $0.30. For a full breakdown of all quarters, see the quarterly earnings table on this page.